Applying biomarkers to clinical practice: A guide for utilizing procalcitonin assays

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2560-2569

  Foushee, Jaime A ^a   Hope, Nancy H ^a   Grace, Edward E ^a  

^a PRESBYTERIAN COLLEGE   (United States)

Author keywords

Antibiotic stewardship; Intensive care unit; Pneumonia; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; PROCALCITONIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CALCITONIN BLOOD LEVEL; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG FATALITY; DRUG UTILIZATION; HUMAN; IMMUNOASSAY; LOWER RESPIRATORY TRACT INFECTION; PATIENT IDENTIFICATION; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BIOLOGICAL MARKERS; CALCITONIN; CLINICAL LABORATORY TECHNIQUES; HUMANS; PNEUMONIA, BACTERIAL; PROTEIN PRECURSORS; UNITED STATES;

EID: 84867600467     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks265     Document Type: Review

References (78)

1. Tang H, Huang T, Jing J et al. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009; 37: 497-507.
2. Hatzistilianou M. Diagnostic and prognostic role of procalcitonin in infections. Scientific World J 2010; 10: 1941-6.
3. Karzai W, Oberhoffer M, Meier-Hellmann A et al. Procalcitonin - a new indicator of the systematic response to severe infections. Infection 1997; 25: 329-34.
4. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 2002; 20: 1-9.
5. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010; 14: 203-13.
6. Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48: 2325-9.
7. Aabenhus R, Jensen JS. Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? Prim Care Respir J 2011; 20: 360-7.
8. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011; 52 Suppl 4: S346-50.
9. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36: 941-52.
10. Wunderink RG. Surrogate markers and microbiologic end points. Clin Infect Dis 2010; 51: S126-30.
11. Brahms. PCT sensitive KRYPTOR Assay Characteristics. http://www.brahms-usa.com/assays (21 September 2011, date last accessed).
12. ThermoScientific/Brahms. Immunoluminometric Assay (ILMA) for the Determination of PCT (Procalcitonin) in Human Serum and Plasma. http://www.brahms-usa.com/manuals/AAL_PCT_LIA_USA_20050111.pdf (21 September 2011, date last accessed).
13. Simon L, Gauvin F, Amre K et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2005; 40: 1386-8.
14. ThermoScientific/Brahms. Immunofluorescent Assay for the Determination of PCT (Procalcitonin) in Human Serum and Plasma. http://www.brahms-usa.com/docs/ifu_825.050_us_brahms-kryptor-pctsensitive.pdf (21 September 2011, date last accessed).
15. Norrby SR, Bjornegard B, Ferber F et al. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 1983; 12: 109-24.
16. Drusano GL, Standiford HC, Bustamante CI et al. The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Eur J Clin Microbiol 1984; 3: 468-70.
17. Neu HC, Aswapokee P, Fu KP et al. Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses. Clin Pharmacol Ther 1980; 27: 677-85.
18. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
19. Martinez AM, Padbury JF, Thio S. Dobutamine pharmacokinetics and cardiovascular responses in critically ill neonates. Pediatrics 1992; 89: 47-51.
20. Wilhelmsson S, Lins LE. Heparin elimination and hemostasis in hemodialysis. Clin Nephrol 1984; 22: 303-6.
21. Cutler RE, Forrey AW, Christopher TG et al. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 1974; 15: 588-96.
22. Burkhardt O, Ewig S, Haagen U et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010; 36: 601-7.
23. Chen SC, Kontoyiannis DP. New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients. Curr Opin Infect Dis 2010; 23: 567-77.
24. Joyce CD, Fiscus RR, Wang X et al. Calcitonin gene-related peptide levels are elevated in patients with sepsis. Surgery 1990; 108: 1097-101.
25. Ahn S, Kim WY, Kim SH et al. Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia. Influenza Other Respi Viruses 2011; 5: 398-403.
26. Chirouze C, Schuhamacher H, Rabaud C et al. Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 2002; 35: 156-61.
27. Delevaux I, Andre M, Colombier M et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003; 62: 337-40.
28. Uzzan B, Cohen R, Nicolas P et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34: 1996-2003.
29. Assicot M, Gendrel D, Carsin H et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-8.
30. Thia KT, Chan ES, Ling KL et al. Role of procalcitonin in infectious gastroenteritis and inflammatory bowel disease. Dig Dis Sci 2008; 53: 2960-8.
31. Hugle T, Schuetz P, Mueller B et al. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exper Rheumatol 2008; 26: 453-6.
32. Chen DY, Chen YM, Ho WL et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with acute adult-onset Still's disease. Ann Rheum Dis 2009; 68: 1074-5.
33. Scire CA, Cavagna L, Perotti C et al. Diagnostic value of procalcitonin measurements in febrile patients with systemic autoimmune disease. Clin Exp Rheumatol 2006; 24: 123-8.
34. Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003; 29: 579-83.
35. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
36. Giamarellos-Bourboulis EJ, Giannopoulou P, Grecka P et al. Should procalcitonin be introduced in the diagnostic criteria for the systemic inflammatory response syndrome and sepsis? J Crit Care 2004; 19: 152-7.
37. Balcl C, Sungurtekin H, Gürses E et al. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003; 7: 85-90.
38. Ruokonen E, Ilkka L, Niskanen M et al. Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand 2002; 46: 398-404.
39. Castelli GP, Pognani C, Cita M et al. Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: diagnosis and monitoring of sepsis. Minerva Anestesiol 2006; 72: 69-80.
40. Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T et al. Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect 2011; 77: 58-63.
41. Gerard Y, Hober D, Assicot M et al. Procalcitonin as a marker of bacterial sepsis in patients infected with HIV-1. J Infect 1997; 35: 41-6.
42. Nobre V, Harbarth S, Graf JD et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177: 498-505.
43. Kopterides P, Siempos I, Tsangaris I et al. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010; 38: 2229-41.
44. Hochreiter M, Kohler T, Schweiger AM et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective trial. Crit Care 2009; 13: R83-9.
45. Iapichino G, Marzorati S, Umbrello M et al. Daily monitoring of biomarkers of sepsis in complicated long-term ICU-patients: can it support treatment decisions? Minerva Anestesiol 2010; 76: 814-23.
46. Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature. Burns 2011; 37: 549-58.
47. Schroeder S, Hochreiter M, Koehler T et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009; 394: 221-6.
48. Bele N, Darmon M, Coquet I et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis 2011; 11: 224-32.
49. Svaldi M, Hirber J, Lanthaler A et al. Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol 2001; 115: 53-7.
50. Riedel S, Melendez J, An A et al. Procalcitonin as a marker for detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol 2011; 135: 182-9.
51. Schuetz P, Christ-Crain M, Thomann R et al. Effect of procalcitonin-based guidelines versus standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-66.
52. Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicenter randomized controlled trial. Lancet 2010; 375: 463-74.
53. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
54. Schuetz P, Chiappa V, Briel M et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171: 1322-31.
55. Muller B, Harbarth S, Stolz D et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7: 10-9.
56. Gibot S, Cravoisy A, Levy B et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350: 451-8.
57. Bauer TT, Ewig S, Marre R et al. CRβ-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260: 93-101.
58. Jensen JU, Heslet L, Jensen TH et al. Procalcitonin increase in early identification of critically ill patients with high risk of mortality. Crit Care Med 2006; 34: 2596-602.
59. Menendez R, Cavalcanti M, Reyes S et al. Markers of treatment failure in hospitalized community acquired pneumonia. Thorax 2008; 63: 447-52.
60. Menedez R, Sahuquillo-Arce J, Reves S et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2011; 11: 1-28.
61. Luyt CE, Combes A, Reynaud C et al. Usefulness of procalcitonin for diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008; 34: 1434-40.
62. Charles PE, Kus E, Aho S et al. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 2009; 9: 49-57.
63. Stolz D, Smyrnios N, Eggimann P et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study (ProVAP Study). Eur Respir J 2009; 34: 1364-75.
64. Bloos F, Marshall JC, Dellinger RP et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 2011; 15: R88-96.
65. Seligman R, Seligman B, Teixeira PJ. Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia. J Bras Pneumol 2011; 37: 495-503.
66. Vincent JL, de Mendonça A, Cantraine F et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793-800.
67. Kotloff R, Ahya V, Crawford S. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170: 22-48.
68. Fishman J, Rubin R. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-51.
69. Jain P, Sandur S, Meli Y et al. Role of a flexible bronchoscopy in immunocompromised patients with lung infiltrates. Chest 2004; 125: 712-22.
70. Stolz D, Stulz A, Müller B et al. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest 2007; 132: 504-14.
71. Uzun G, Solmazgul E, Curuksulu H et al. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J Exp Med 2007; 213: 305-12.
72. Jeandrot A, Richard JL, Combescure C et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from noninfected diabetic foot ulcers: a pilot study. Diabetologia 2008; 51: 347-52.
73. Shlaes DM, Gerding DN, John JF Jr et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-99.
74. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011; 53: 379-87.
75. Heyland DK, Johnson AP, Reynolds SC et al. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011; 39: 1792-9.
76. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
77. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
78. American Thoracic Society/Infectious Diseases Society of America: guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.